van Rooijen & Partners is proud to have mediated a business deal between NascaCell IP and Aventis. <<
Press release.
NascaCell announces a collaboration agreement with Aventis
MUNICH, Germany, September 13, 2004
NascaCell announced today that it has entered into a collaboration with Aventis. Under a framework agreement NascaCell will provide Aventis with access to its proprietary aptamer technology. Aventis is a global pharmaceutical company with a commercial presence in approximately 85 countries and products available in more than 170. Aventis has been part of the Sanofi-Aventis group since August 20, 2004.
“We are delighted to have the opportunity of this collaboration with Aventis. It further establishes the use of aptamers for accelerated target validation " said Dr. Andreas Jenne, CEO of NascaCell IP.
Aptamers are synthetic oligonucleotides that are able to bind to target proteins with high affinity and specificity. Because of the small molecule-like binding characteristics of aptamers, they typically show strong inhibition of protein function. NascaCell offers aptamers as tools for accelerated target validation and drug discovery.
Dr. Lucio A.A. van Rooijen at van Rooijen & Partners (www.vr-p.com) mediated the business deal.
About NascaCell (www.nascacell.de):
NascaCell, located in Munich, Germany, is a biotech company supporting pharma and biotech companies in their endeavor to enhance the development of small molecule drugs against disease-causing protein targets. Customer service projects and strategic partnerships for target validation, functional proteomics and drug discovery are the key components of our business. NascaCell is a global leader in the automated production and marketing of custom aptamers. Aptamers are synthetic drug-like molecules that can specifically knock-down protein functions in living cells and organisms. Their rapid production and convenient handling mean aptamers can be used in numerous drug discovery applications, such as animal studies or high throughput drug screening.
For further information, please contact:
NascaCell IP GmbH
Dr. Andreas Jenne, CEO
Phone: +49-89-547272-0
Fax: +49-89-547272-22
E-Mail: a.jenne@nascacell.de